THE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences

Similar documents
Dermal drug testing. Pharmacokinetic, pharmacodynamic and bioequivalence studies in the dermis

Your bridge to. better medicines

What dofm Adds to Pharmacokinetics-Based BA Approaches

LAB EXPERTS AT YOUR SIDE Over twenty years of experience

The use of membrane-free OFM for studies into the PK-PD of large molecules

ABF Pharmaceutical Services GmbH

Introduction to Drug Design and Discovery

Guideline for the quality, safety and efficacy of follow-on biological medicinal products

synlab clinical trial

MRC-NIHR National Phenome Centre

the biomarker testing laboratory

AT A GLANCE. inventivhealthclinical.com

Eurofins ADME BIOANALYSES Your partner in drug development

Bioanalytical Support to In Vitro Studies

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Generic drugs and their role in bringing next generation products: An FDA perspective

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Trend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective

Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety

About Clinical Trials: What They Can Mean For You?

Changes Impacting Bioequivalence Inspections: What s New?

R&D Portfolio Planning In- and Out-licensing of Medicines

5 key characteristics

FORMULATING FOR MICRONEEDLE DELIVERY. Professor Finn Bauer

PPD LABORATORIES COMPREHENSIVE SERVICES

ABOUT KYMOS. Our commitments. Quality assurance. Location

Optimisation de votre programme de développement

Role of Academic Investigators in Drug Development

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar

NUVISAN GROUP. Our Philosophy

Comments and suggestions from reviewer

TECHNOLOGY READINESS LEVELS (TRLs)

Healthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation

THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS

World-leading LC/MS/MS technology for quantitation and identification API LC/MS/MS System

Bioanalytical Best Practice in Australia a CPR perspective. by Andrew Dinan Senior Director Bioanalytical Services CPR Pharma Services, Australia

About HFL. Markets & services. Markets & services. Qualitative MS: Pharmaceutical Applications. Regulatory Framework

PHARMACEUTICAL BIOANALYSIS BIOANALYSIS SERVICES. Bioanalytical Expertise for Large and Small Molecules

leading the way in research & development

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)

INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES.

LETI-HEALTH. Adrienne Pervès Deputy Director LETI Technologies for Biology and healthcare Department

Engage with us on Twitter: #Molecule2Miracle

Documentation requirements for an initial consultation

S3A:Note for guidance on toxicokinetics: The assessment of systemic exposure in toxicity studies. Q&A: FOCUS ON MICROSAMPLING

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

SHANGHAI MEDICILON INC.

QPS Neuropharmacology Overview

Bioanalytical sciences Helping you get the most from your precious samples

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development

Pharmaceutical LC/MS Solutions from Agilent Technologies

Case Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH)

Biopharmaceuticals A Regulatory Perspective

Presentation Outline. Introduction Sources of Challenge for BE study

Drug Discovery and Development PHG 311. Prof. Dr. Amani S. Awaad

Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment

The Best Companion! KOREA MEDICINE RESEARCH INSTITUTE - CRO Based on Reliability and Promise, KMRI will accompany you

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

REIMAGINING DRUG DEVELOPMENT:

Biosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

bioanalytical challenge Patrick Bennett PPD Biomarker Laboratories November 2015

SPEED UP YOUR TIME TO MARKET

Dermal Studies at CBI

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

Projet EuCP European Certified Pharmacologists. Utrecht mars

INTRODUCTION TO PHARMACOLOGY

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner

What is the purpose of this website?

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

Asterand Bioscience Strategic Alliances

GDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS

Concept paper on the development of a guideline on quality and equivalence of topical products

CAMAG DBS-MS 500 DRIED BLOOD SPOT EXTRACTION SYSTEM FOR LC-MS

CONTENTS. The bottleneck in Drug Discovery. Syncrosome s Preclinical Offer. In short. Drug Efficacy services. Key facts. Bioavailibility and CNS-PK

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry

Drug-Device Combination Product Development: INDs for Device Companies

Guideline/Guidance Comparison on Ligand Binding Assays (LBA)

Guideline/Guidance Comparison on Ligand Binding Assays (LBA)

Preclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements

Date/Lecturer Class Topic Readings 01/28/10 Brookman

Stem cell and cell therapeutics research in Lithuania. Bernardas Morkunas Head of Business Development

! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

Official Letter from the DOH

AIT Austrian Institute of Technology

E O. The EORTC Strategy for New Drug Development THE EORTC PROVIDES: The EORTC is the leading pan-european partner for high-quality clinical research

Current Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays

GMP. Safeguard The Patient s Health.

Qualifying SPR immunogenicity assays Dr. Christian Kühne

CAMAG. Jack Henion, Emeritus Professor Cornell University and VP of R&D. at Quintiles Bioanalytical and ADME Labs, USA

Transcription:

THE INNOVATION COMPANY HEALTH Institute for Biomedicine and Health Sciences

Our central activity is innovative applied research that bridges the gap between basic research and industrial applications. We are well placed to meet the needs of both, science and business. High quality standards, fast decisions, excellent communication and strong team work make us a valued partner for the pharmaceutical industry, medical device manufacturers and health system institutions. Thomas Pieber, MD, Professor of Medicine Director Contact JOANNEUM RESEARCH Forschungsgesellschaft mbh HEALTH Institute for Biomedicine and Health Sciences Main office and laboratory, Graz: Neue Stiftingtalstrasse 2 8010 Graz Phone +43 316 876-40 00 Fax +43 316 876 9-40 00 health@joanneum.at www.joanneum.at/health JOANNEUM RESEARCH Forschungsgesellschaft mbh HEALTH Institute for Biomedicine and Health Sciences Local office, Vienna: Haus der Forschung Sensengasse 1,1090 Wien Phone +43 316 876-40 00 Fax +43 316 876 9-40 00 health@joanneum.at www.joanneum.at/health 2

HEALTH Institute for Biomedicine and Health Sciences BRIDGING BOUNDARIES No other field is as dependent on interdisciplinary collaboration to bring new ideas to market as medicine. We work in a close strategic alliance with the Medical University of Graz and our director, Prof Thomas Pieber MD, is also the director of the clinical department for endocrinology and metabolism at the University. Our team consists of around 70 technical and scientific employees. We work closely with a further 120 medically oriented specialist personnel from the Medical University of Graz. Together, we work to translate ideas and technologies from medicine, pharmaceutical science and health services research into marketable products and services. Research services Quality Tissue-specific pharmacokinetic and pharmakodynamic studies Bio- and pharmaceutical analysis Metabolomics / Biomarker research Medical device development & evaluation Health economics & outcome research Integrated health care concepts and planning We set high quality standards for our services and products. As our partner, you can rely on the application of international quality standards right from placing your order up to delivery of the final product/service. We operate according to the following guidelines: EN ISO 9001:2008 EN ISO 13485:2012 GLP Our customers are welcome to assess our facilities and quality standards on-site at any time. 3

Tissue-specific pharmacokinetic and pharmakodynamic studies We examine pharmacokinetic (PK) and pharmacodynamic (PD) profiles of new drugs as well as the bioequivalence of new pharmaceutical formulations. We carry out biomarkerbased and metabolomic studies to pinpoint the causes of inflammatory diseases. We have the capacity to perform pre-clinical ex vivo and in vivo, as well as clinical in vivo studies, using microdialysis and our patented Open-Flow Microperfusion method. Our services preparing study protocols submitting ethical applications executing pre-clinical and clinical studies performing and validating bioanalytical procedures statistically analyzing the data We focus on the target tissue level Dermatology: Transport routes and effects of drugs within the dermal layer after topical or systemic administration (e.g., topical glucocorticoids or systemic antibodies in the case of psoriasis) Endocrinology: Transport routes and effects of drugs in adipose tissue (e.g., insulin) Neurology: Transport across the blood-brain barrier (BBB), dose-response effects when the BBB is bypassed, monitoring of BBB function (e.g., highly lipophilic and psycho- and neuropharmaceuticals) OFM-probe for pharmacokinetic and pharmacodynamic studies in dermal and adipose tissue 4

Advantages of Open-Flow Microperfusion (OFM) Direct in vivo access to the interstitial fluid and to the interstitium s whole biochemical information continuous sampling of diluted, unchanged tissue interstitial fluid no limitation in substance size (even cells), lipophilicy or protein binding effects continuous multi-analyte sampling and PK-PD analysis High-end laboratory GLP certified We are specialized on microliter sample volumes and picomolar analyte concentrations with state-of-the-art mass spectrometry. Study planning, electronic data capture and management and statistics Having a profound understanding of medical research, we combine electronic data capture and management with long-term expertise in reliable and stressable statistical analysis according to GCP and 21 CFR Part 11. OFM-material CE-labeled catheters and small, wearable, multi-channel pumps for (pre-)clinical PK and PD-studies Contact: Dr Frank Sinner +43 316 876-40 02 frank.sinner@joanneum.at 5

Bio- and pharmaceutical analysis We develop, validate, optimize and automate innovative bioanalytical methods for high-throughput analyses that can be used by medical researchers and in the pharmaceutical industry. We can analyse microliter sample volumes and picomolar analyte concentrations with stateof-the-art bioanalytical methods. We offer our services GLP compliant - if required. Our services Sample Preparation from various biological sample matrices (serum, plasma, interstitial fluid, tissue, cell cultures) and drug formulations. Bioanalysis From innovative analytical methods to quality controlled analysis of human and animal blood and tissue samples. Pharmaceutical analysis is performed on pharmaceutical raw materials and formulations, e.g. drug analysis, cleaning validation, quantitative testing and testing for impurities. Cleaning validation From optimizing sampling methods, the development of high sensitive and selective analytical methods and validation according to international standards. High-throughput analysis High-end metabolomic wetlab Metabolites including acyl-coa enzymes, products of energy metabolism, isotope-labeled tracer molecules, etc. Drug analysis Polyamines 6

Metabolomics/ Biomarker research The application and optimization of innovative analytical services for the investigation of metabolic processes is our focus. We combine medical, biological, biochemical, bioanalytical, information technology and statistical expertise for basic research, drug development, diagnostics and personalised medicine. Our services Study design medical as well as biological and statistical expertise Sampling Freeze clamp tissue samples, serum, plasma, cell culture, yeast Sample storage, sample preparation LC/FTMS-analysis Data analysis data conversion, peak detection, alignment, grouping, data filtering Statistics multivariate statistical methods, regression models, neural networks Metabolite database Determination of unknown substances Contact: Dr Christoph Magnes +43 316 876-42 01 christoph.magnes@joanneum.at 7

Medical device development and evaluation We are ISO 13485:2012 certified and develop technologies relevant to medical sensors, clinical decision support and minimally-invasive in vivo sampling. We also support the development of medical devices through all stages of the medical device life cycle. We aim to help you develop products that meet medical needs, high demands of medical staff and patients as well as stringent regulatory, safety and quality requirements. Our services Assessment and evaluation Design-Development-Verification Clinical data and evaluation Market launch & production Market and technology surveillance Quality and risk management 8

Medical sensors We focus on implementing various sensor technologies into applications for the clinical environment. We drive the development of new sensing methods from fundamental ideas to experimental models and prototypes for preclinical and clinical testing. Optical and electrochemical sensors for in vivo and ex vivo monitoring Point of care systems Home monitoring Evaluation of sensor systems Clinical decision support systems We develop smart software systems to support complex clinical processes focussing on usability. It is our aim to support professional medical decision making and adequate patient care. Work-flow management and decision support for mobile devices, focusing on optimum usability Implementation of clinical protocols and algorithms Information extraction from medical free-text documents Usability studies with patients and clinical professionals Clinical studies for software validation Contact: Dr Frank Sinner +43 316 876-40 02 frank.sinner@joanneum.at 9

Health economics & outcome research We support you by offering our unbiased, evidence- and science-based expertise in the areas of health care and pharmacoeconomics, market analysis, horizon scanning, regulatory affairs and reimbursement, as well as in the scientific and economic evaluation of health care programs. Our services Early assessment of new technologies and products Health economics and reimbursement Market analysis and horizon scanning Medical and economic evaluations of health care Know How Comprehensive analyses and solutions Interdisciplinary approaches Information about decision-making processes and requirements within the health care system In-depth knowledge of the health care system and services Expertise in specific diseases and indications Application of a wide range of scientific methods and study designs Code of conduct In our work, we place the highest value on the use of methods that have been scientifically established and supported, as well as on unbiased results derived by applying principles of both scientific rigor and objectivity. We work toward the continuous improvement of health care in Austria and other countries and, for this reason, we feel that we are obliged to the interests of our society. We are particularly keen to represent the interests of patients insofar as possible, with the ultimate goal to benefit the whole of society with our concepts, expertise and analyses. 10

FOTOLIA, nyul Integrated health care concepts and planning We assist healthcare decision-makers and service providers in the development, implementation, monitoring and evaluation of integrated health care operations. We increase the visibility of your services in therapeutic, diagnostic and nursing settings and help you to unlock your full potential as a healthcare provider, support organization, hospital, insurance agency, association, clinic or doctor in a private practice. Our services Structural planning Procedural planning Development of care management programs Medical and economic evaluations in the health care system Contact: Dr Wolfgang Habacher +43 316 876-44 01 wolfgang.habacher@joanneum.at 11

JOANNEUM RESEARCH Forschungsgesellschaft mbh HEALTH Institute for Biomedicine and Health Sciences Main office and laboratory, Graz: Neue Stiftingtalstrasse 2 8010 Graz Phone +43 316 876-40 00 Fax +43 316 8769-40 00 health@joanneum.at www.joanneum.at/health JOANNEUM RESEARCH Forschungsgesellschaft mbh HEALTH Institute for Biomedicine and Health Sciences Local office, Vienna: Haus der Forschung Sensengasse 1,1090 Wien Phone +43 316 876-40 00 Fax +43 316 8769-40 00 health@joanneum.at www.joanneum.at/health prm pbf 14 208 As of June 2014 THE INNOVATION COMPANY